Equitable Holdings Inc. Makes New Investment in Danaher Corporation $DHR

Equitable Holdings Inc. purchased a new stake in shares of Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,651 shares of the conglomerate’s stock, valued at approximately $9,109,000.

Several other large investors have also recently modified their holdings of DHR. BlackRock Inc. bought a new stake in Danaher during the 2nd quarter valued at about $10,492,520,000. State Street Corp lifted its stake in shares of Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock worth $6,345,529,000 after buying an additional 472,608 shares in the last quarter. Capital International Investors lifted its stake in shares of Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after buying an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Danaher by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after buying an additional 1,334,221 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after buying an additional 1,517,904 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DHR. Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Evercore reiterated an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. Stifel Nicolaus reduced their target price on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. DZ Bank started coverage on Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $228.91.

Danaher Stock Up 0.2%

DHR opened at $215.74 on Friday. The stock has a market capitalization of $151.67 billion, a price-to-earnings ratio of 38.32, a PEG ratio of 2.68 and a beta of 0.78. The firm has a 50 day moving average price of $198.69 and a 200-day moving average price of $192.35. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the company posted $0.77 earnings per share. Equities research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.